Evidence map›Paper›PMID 41667458›Full record

ArticleNature communications2026

Degraders of the dengue virus capsid protein exhibit differentiated pharmacology relative to capsid inhibitors.

Antara Chakravarty, Lu-Ning Wang, Ryan P Golden, Zhengnian Li, Katherine A Donovan, Oshri Afanzar, Yupeng Zhang, Eric S Fischer, Nathanael S Gray, Priscilla L Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Antara Chakravarty *Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5440-990X
Lu-Ning Wang *Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3908-7946
Ryan P GoldenDepartment of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0009-0004-7113-007X
Zhengnian LiDepartment of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5851-8011
Katherine A DonovanDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8539-5106
Oshri AfanzarDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.
Yupeng ZhangDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.
Eric S FischerDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7337-6306
Nathanael S GrayDepartment of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5354-7403
Priscilla L YangDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA. ply@stanford.edu.ORCID 0000-0001-7456-2557

Funding

Small molecule-induced degradation of dengue proteins as an antiviral strategyR01AI148632 · NIAID · STANFORD UNIVERSITY · PI GRAY, NATHANAEL SCHIANDER, YANG, PRISCILLA LI-NING · 2020 to 2024
$4.1M
NIAID NIH HHS R01 AI148632
6 · The paper itself

Abstract

Due to the limited size of viral genomes, most viral proteins are multifunctional; yet most direct-acting antivirals are designed as single-function inhibitors. The dengue virus (DENV) capsid protein serves as a building block for new virions while also interacting with multiple host factors to remodel the cellular environment. Using established capsid inhibitor ST148 as a targeting ligand, we develop a DENV capsid degrader, RPG-01-132, that exhibits a broadened spectrum of activity against the four DENV serotypes and an ST148-resistant mutant virus. Using multiple approaches, we show that RPG-01-132's sub-micromolar antiviral activity is due to CRL4

Indexed as

Antiviral AgentsCapsidCapsid ProteinsDengue VirusAnimalsCell LineHumansProteolysisVirionVirus AssemblyVirus ReplicationAntiviral AgentsCapsid Proteins

Identifiers

PMID41667458
PMCPMC13003150

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.